<DOC>
	<DOC>NCT03051100</DOC>
	<brief_summary>The purpose of this study is to determine if triplet therapy with bempedoic acid (ETC-1002) 180mg, ezetimibe 10mg, and atorvastatin 20mg is effective and safe versus placebo in patients with elevated LDL cholesterol.</brief_summary>
	<brief_title>Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Fasting LDLcholesterol between 130 189 mg/dL at screening following washout of all LDLClowering drugs and nutritional supplements Men and nonpregnant, nonlactating women Sufficiently stable and suitable to undergo washout of all LDLClowering drugs and nutritional supplements for 12 weeks Fasting blood triglycerides greater than or equal to 400 mg/dL Body Mass Index (BMI) greater than 50 kg/m2 History of clinically significant cardiovascular disease History of type 1 or type 2 diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>hyperlididemia</keyword>
	<keyword>LDL</keyword>
	<keyword>cholesterol</keyword>
</DOC>